Bexorg Announces Multi-Program Research Collaboration With Biohaven To Identify, De-Risk, And Advance Next-Generation Therapies For CNS Disorders

Author: Benzinga Newsdesk | June 10, 2025 02:01pm

Bexorg, Inc., a pioneering techbio company working to decode the human brain and advance new therapies for central nervous system (CNS) disorders, today announced a multi-program research collaboration with Biohaven Ltd. (NYSE:BHVN) to identify, de-risk, and advance next-generation therapies for CNS disorders. As part of the collaboration, Bexorg's novel whole-brain discovery platform will be used to demonstrate target engagement in relevant cell types and tissues and generate novel biomarkers, pharmacokinetic and pharmacodynamic relationships, and other mechanistic data to support two preclinical development programs at Biohaven.

Posted In: BHVN